Imophoron
Bristol
About Imophoron
Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $5.4M
- Funding stage: Seed
- Last round: Seed (Jul 2023)
- Website: imophoron.com
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/imophoron-47920 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.